Podcasts about AES

This Is Why Everyone Else Is Getting Promoted Faster Wondering why you're stuck while your peers keep getting promoted? It's not about tenure or luck—it's about strategy. In this video, we break down the hard truth behind why others are getting promoted faster than you. Based on the career journey of a former VP of Sales who jumped multiple levels by age 29, you'll get a clear 4-step framework that helps you outperform, gain leverage, and control your own promotion path. If you're tired of waiting your turn, or feel like your hard work isn't being recognized, this is your wake-up call. Learn how to become undeniable, run your own promotion “sales cycle,” and make it impossible for leadership to overlook you. Perfect for SDRs, AEs, and any high-performer in a competitive sales org. RESOURCES DISCUSSED: Join our weekly newsletter - https://hubs.li/Q02NJQmg0 Things you can steal - https://linktr.ee/30mpc Save $50 on any 30MPC course - https://www.30mpc.com/courses with code “PODCAST” Free Sales Templates, Scripts and Guides - https://www.30mpc.com/toolkit

In this episode, Jason and Clara Johnson kick off a new behind-the-scenes series with the Outbound Squad sales training team. They shared how SDRs can improve cold call qualification to boost pipeline conversion and set AEs up for success. Check out more free content and get coaching at ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://outboundsquad.com.⁠

Why you should listenRob Fegan shares the exact 4-phase framework he used to transform his Microsoft partner business from zero to millions in annual revenue—and how SMB partners can replicate this success even as "small fish" in a 30,000-person sales ecosystem.Learn how to leverage Microsoft's Commerce Incentives Fund to access thousands in funded engagements per customer, essentially getting Microsoft to pay you to deploy their solutions while you focus on high-margin services.Discover why connecting with AI specialists (not just AEs) is the key to unlocking Microsoft's FY26 priorities, and how to position your messaging so Microsoft's field teams become your biggest sales asset instead of just another vendor relationship.You're running a solid Microsoft partner business, delivering real results for clients, but you feel completely invisible to Microsoft's massive sales organization. You watch bigger partners effortlessly access pipeline opportunities, co-sell motions, and vendor support while you're stuck fighting for scraps. You know the opportunity is there—Microsoft has 30,000 salespeople who could be feeding you qualified leads—but you have no idea how to cut through the noise when you're just a 1-10 person shop.In this episode, I sit down with Rob Fegan from RYZE Partners who spent 15 years building and scaling Microsoft partner businesses before a successful exit. Rob breaks down his proven 4-phase framework that turns Microsoft's field teams into your biggest sales asset, even as a small partner. We dive into the four critical areas most partners get wrong, why SMB partners are suddenly Microsoft's top priority after years of enterprise focus, and the specific funded programs that can inject thousands of dollars per engagement into your business. If you're tired of being stuck, overlooked, and sidelined while bigger partners dominate the conversation, this episode gives you the exact playbook to change that.About Rob FeganRob Fegan is the founder of Venvito and co-founder of RYZE Partners, where he helps Microsoft SMB partners go from invisible to in-demand. After 15+ years in the Microsoft ecosystem, Rob built his own Microsoft practice from zero to millions in annual revenue before a successful exit. Now he's on a mission to help 10,000 Microsoft partners escape what he calls "SOS Mode" - being Stuck, Overlooked, and Sidelined - through his proven frameworks for demystifying selling WITH Microsoft. Rob's approach has helped partners transform from vendor status to becoming Microsoft's go-to referral sources, turning field teams into their biggest sales asset.Resources and LinksRyze-partners.comVenvito.netRob's LinkedIn profilePrevious episode: 639 - How to Stop ChatGPT from Lying to You (AI PhD Reveals the Fix) with Garima AgrawalCheck out more episodes of the Paul Higgins PodcastSubscribe to our YouTube channel: @PaulHigginsMentoringJoin our newsletterSuggested...

OEG celebrates 500 offshore turbine toilet installations while BlackRock acquires AES for $38 billion, signaling continued investment despite global wind auction slowdowns and European wind droughts. Sign up now for Uptime Tech News, our weekly email update on all things wind technology. This episode is sponsored by Weather Guard Lightning Tech. Learn more about Weather Guard's StrikeTape Wind Turbine LPS retrofit. Follow the show on Facebook, YouTube, Twitter, Linkedin and visit Weather Guard on the web. And subscribe to Rosemary Barnes' YouTube channel here. Have a question we can answer on the show? Email us! Welcome to Uptime News. Flash Industry News Lightning fast. Your host, Allen Hall, shares the renewable industry news you may have missed. Allen Hall 2025: There's good news today from the wind energy sector, and it starts of all places with toilets. OEG and Aberdeen Headquartered company just reached a milestone. They've installed their 500th in turbine welfare unit across the UK's offshore wind sector. If you've ever worked on an offshore wind turbine, you know why this matters. These aren't just convenience facilities. Their dignity and their safety. The other difference between a dangerous transfer to a standby vessel and staying on the job. The units operate in the harshest offshore conditions with no external power or water. Nine offshore wind farms now have these facilities and they're making offshore work accessible for [00:01:00] women helping retain a more diverse workforce. And while OEG celebrates 500 installations, something much larger is happening in the American Midwest. Gulf Pacific Power. Just completed a major transaction with NL Green Power North America. Gulf Pacific acquired all of E L's interest in five operating wind facilities, totaling over 800 megawatts of capacity. The portfolio includes Prairie Rose in Minnesota, Goodwill and Origin, and Rocky Ridge in Oklahoma, and a facility in North Dakota. Projects with long-term power purchase agreements and high credit counterparties. And then there's BlackRock. The world's largest asset manager is placing a $38 billion bet on American clean energy. They're close to acquiring power Giant a ES, which have give BlackRock ownership of nearly eight gigawatts of wind power capacity. A [00:02:00] ES leads in sign deals with data center customers with artificial intelligence driving unprecedented electricity demand. That positioning matters. The weather numbers tell their own story about wind's challenging year. Most of Europe recorded wind speeds four to 8% below normal in the first half of this year. The wind drought curtailed generation in Germany, Spain, France, and the United Kingdom. But the Northeastern United States saw winds seven to 10% above average in parts of Norway, Sweden, and Northern China also benefited. And in storm, Amy, which is passing through the uk, it drove wholesale electricity prices negative for 17 hours. 20 gigawatts of wind power flooded the grid and the grid paid users to consume electricity. Too much wind, not enough demand. The offshore wind industry faces real headwinds. Global awards fell more than 70% in the first nine months of this year. Of about 20 gigawatts of expected auctions, [00:03:00] only 2.2 gigawatts have been awarded. Germany, the Netherlands and Denmark are preparing new frameworks to restore investor confidence and Japan designated two promising offshore zones, but confidence there is still shaken when Mitsubishi pulled out of its first auction due to some sorry costs. So here's what we have. An Aberdeen company celebrating 500 toilet installations that transform working conditions. A Midwestern power company expanding its wind portfolio by 800 megawatts and the world's largest asset manager, betting $38 billion on American energy infrastructure. All while offshore auctions stall globally, all while Europe experiences a wind drought and the UK experiences at times too m...

We would LOVE to hear what you think. Please drop a line.The Sync Soundtrack with Marcus MandersonMarcus Manderson (@dafingaz) is a composer and producer who specializes in sync licensing, trailers, and custom music for global brands. His dynamic work has graced STARZ's BMF and shined across MTV, BET, Bravo, the NBA, NFL, NHL, MLB, and more. Recent highlights include a Netflix trailer placement and the musical opening for the Lil Jon x Pitbull world tour.Beyond creation, Marcus is a leading voice in the sync and production music community. He hosts panels at SXSW, NAMM, AES, and other major events, runs global writing camps with Level Up Music Productions, and leads workshops that bring music production education to students around the world.At the core, Marcus believes music is more than sound. It is strategy, storytelling, and connection—and his mission is to help creators and brands unlock that power.Join the conversation as he breaks down the art and science of music for media, reveals behind-the-scenes insights from high-profile placements, and shares practical guidance for navigating licensing, composition, and collaboration in a fast-paced industry.Support the show

Get My Book On Amazon: https://a.co/d/avbaV48DownloadThe Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/1 On 1 Coaching Application: https://hunterwilliamscoaching.carrd.co/Book A Call With Me: https://hunterwilliamscall.carrd.co/Supplement Sources: https://hunterwilliamssupplements.carrd.co/Amazon Storefront: https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DYSocials:Instagram: https://www.instagram.com/hunterwilliamscoaching/Podcast: https://hunterwilliamspodcast.buzzsprout.com/Video Topic Request: https://hunterwilliamsvideotopic.carrd.co/In today's video I unpack amlexanox—an old anti-inflammatory/allergy drug with surprising metabolic effects. I share my first encounter with it in the research-chem world, what I noticed subjectively, and then dive into mechanisms (IKKε/TBK1 inhibition, catecholamine resensitization, beige fat), rodent data, the Phase 2 human trial (150 mg/day), safety, dosing, who seems to respond best, and how I'm stacking it inside Bio Ignite. If your goal is fat loss with stubborn adipose inflammation, this is worth understanding.0:00 - Welcome + what today's video covers0:28 - How I first found “AM Lox” browsing catalogs1:06 - Cycling off SLU-PP-332 and first personal trial1:40 - Noticing dryness/ab definition; early under-dosing2:12 - 2025 “sugar diet” + hunting for FGF21 boosters2:40 - Finding data that amlexanox increases FGF213:02 - Literature dosage (100–150 mg) vs my early dose3:38 - Why I think it's a useful fat-loss rotation tool4:24 - Channel/hosting update + where to find my videos5:08 - Slides start: what amlexanox is/was used for6:00 - Core mechanism: IKKε/TBK1 → PDE3B → cAMP resistance7:16 - IL-6→STAT3 hepatic signaling + beigeing via FGF218:30 - Big-picture benefits: inflammation, insulin sensitivity, glycemia10:32 - Human data: Phase 2 trial (150 mg/day x 12 weeks)11:10 - Modest/variable weight change; who improved most12:37 - Practical takeaways: glycemia, liver fat, insulin sensitivity14:12 - Dosing in practice (50 mg caps, TID = 150 mg/day)15:12 - Responder phenotype: high adipose inflammation16:00 - Who benefits most + variability at similar body fat17:56 - Study roll-up and mechanism recap18:52 - Final thoughts, use-cases, and product note (Bio Ignite)19:54 - Thank you + where to grab the peptide cheat sheetWhat You'll LearnWhy amlexanox can “release the brakes” on fat-burning by inhibiting IKKε/TBK1 and restoring cAMP/catecholamine responsiveness.How it raises IL-6 transiently in adipose, activates STAT3 in the liver, suppresses gluconeogenesis, and increases FGF21 to promote beige fat programs.The mouse vs. human gap: robust fat loss in mice; in humans, clearer improvements in A1c, fructosamine, liver fat, insulin sensitivity—especially when adipose inflammation is high.Dosing used in the Phase 2 trial: 50 mg TID (total 150 mg/day) for 12 weeks.Safety snapshot: no serious AEs attributed to amlexanox in metabolic trials; most common was a transient rash.Timestamps (exact to the transcript)What you'll learn

If your outbound is optimised for meetings, not conversations, you're burning cash and trust.We sit down with Joey Gilkey (CEO, Titan X) and Adem Manderovic (Closed Circuit Selling, CRO School) to rebuild B2B outbound so it actually drives revenue. We unpack why the SDR-AE factory failed, how to get 25% connect rates, and how to use first-party signals to guide timing, ads, and follow up.Joey shows why he pays SDRs to create completed conversations and rigorous disposition buckets. Adem explains cataloguing and channel validation so marketing stops guessing and starts planning around real timing. We dig into audience activation using opt-in texts and VSLs, and why “buyer intent” data isn't the shortcut you think it is.Tune in and learn:+ A practical B2B outbound strategy built on conversations and 6 disposition buckets+ Why the SDR-AE model and Predictable Revenue broke outbound (and what replaces it)+ Why pipeline coverage and meeting quotas mislead teams, and what to measure insteadThis is a must-watch if you're a B2B revenue leader. Stop chasing low-value meetings and start engineering high-value conversations that inform ads, timing, and deals.-----------------------------------------------------

In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas." TRANSCRIPT The disclosures for guests on this podcast can be found in the transcript. Dr. Ece Cali: Welcome to this episode of JCO Article Insights. This is Dr. Ece Cali, JCO editorial fellow, and today I am joined by Dr. Martin Wermke, Professor for Experimental Cancer Therapy at Dresden University of Technology, to discuss the manuscript “Phase 1 Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-like T-Cell Engager Obrixtamig in Patients with DLL3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.” Obrixtamig is a bispecific T-cell engager that binds to DLL3 on tumor cells and CD3 on T-cells. This manuscript presents the phase 1A dose escalation results of Obrixtamig in patients with DLL3+ small cell lung cancer and neuroendocrine carcinomas. In this study, 168 patients were treated with Obrixtamig across four different dosing regimens. 49% of the patients had small cell lung cancer, 42% had extrapulmonary neuroendocrine carcinoma, and 8% had large cell neuroendocrine carcinoma of the lung. Patients received a median of two prior lines of therapy. 33% of the patients had brain metastases at baseline. Of note, this trial did not mandate baseline brain imaging. Maximum tolerated dose was not reached. 88% of the patients experienced a treatment-related adverse event, however, only 3.6% of the patients had to discontinue treatment due to treatment-related AEs, and dose reduction due to treatment-related AEs was documented in 2.4% of the patient population. Similar to the other DLL3-targeted bi-therapies, the most common adverse events included CRS in 57%, dysgeusia in 23%, and pyrexia in 21% of the patients. CRS events were mostly mild. They occurred more frequently in the first two to three doses. 9% of the patients experienced ICANS, of which 3% were graded as Grade 3 or higher. And let's review the efficacy results. Responses were only seen in patients who received 90 microgram per kg or more once weekly or once every three weeks dosing. The objective response rate in patients who received an effective dose was 28%. If we review by tumor type, 21% of the small cell lung cancer patients, 27% of the extrapulmonary neuroendocrine carcinoma patients, and 70% of the large cell neuroendocrine carcinoma patients had objective response. Median duration of response was 8.5 months, though this data is immature due to short follow-up. Dr. Wermke, DLL3-targeted bispecific T-cell engagers are reshaping the treatment landscape of small cell lung cancer. This trial investigates Obrixtamig in other high-grade neuroendocrine tumors as well. Can you put this trial into context for us and explain why it may represent an important step forward? Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to discuss our data today. I think the data with Obrixtamig in small cell lung cancer are largely similar to what has been observed with other bispecific T-cell engagers such as tarlatamab with respect to the response rate and duration. It has, however, been to be mentioned that BI 1438001 had a bit more liberal inclusion criteria than other trials around. You already mentioned the fact that we allowed the inclusion of patients without mandatory brain imaging, which led to some patients having their brain mets been diagnosed during the treatment with obrixtamig and then adding to the progressive disease patients. That is something which was not the case with the tarlatamab trials where you really had to have a brain imaging before, and in the Phase 1 trial you were even required to treat the brain mets before you included the patient. So it is a bit different, more poorest patient population. I think the trial adds on existing data by being the first trial to also include non-SCLC neuroendocrine carcinoma of other origin, for example from the gastrointestinal tract, and also by including large cell neuroendocrine carcinoma of the lung, which is a really hard to treat pulmonary neoplasm which currently lacks any standardized treatment. So that is really a step forward which we will build on in the future. Dr. Ece Cali: And one thing I would note in this trial, only patients with tumor expressing DLL3 were enrolled. Can you tell us a little bit more about this target, DLL3 in the context of neuroendocrine tumors, and does DLL3 expression predict clinical outcomes after treatment with DLL3 BiTEs, or do we actually need other predictive biomarkers for these novel agents? Dr. Martin Wermke: Yeah, thank you. That's a pretty interesting question. First of all, DLL3 is an atypical notch ligand, which is expressed by the majority of neuroendocrine carcinomas, virtually absent on healthy adult tissues. Therefore, turning it really into a bona fide target for T-cell engaging therapies, pretty low risk for on-target off-tumor side effects. We found that in all the patients we screened, we had an expression rate of about 94% in small cell lung cancer, 80% of large cell neuroendocrine carcinoma of the lung were positive, and also about 80% of the extrapulmonary neuroendocrine carcinoma. So it's really a high prevalence. So the fact that we only included DLL3+ tumors still means we included most of the patients that presented with these diseases. I think at the moment there are no data suggesting a clear-cut association between DLL3 expression levels and outcome on DLL3 CD3 T-cell engagers. There's also not a lot published. If you want to find this out for tarlatamab, you have to look into their patent to really see the data, but it's not clear-cut and I'm sure we need other markers to complement that. And I think what probably plays a major role is intrinsic T-cell fitness. So the question how really diseased your T-cells are, how old you are, because age also correlates with the fitness of the immune system, and other patient characteristics such as tumor burden, we've seen all across the board that the higher the tumor burden, the lower the rate of prolonged response is in such trials. And I also think we need to focus on other components of the tumor microenvironment. So see how high the T-cell infiltration with obrixtamig is and how abundant suppressive elements like regulatory T-cells or myeloid-derived suppressive cells are. That is work which is currently being done. Data are emerging, but I don't think that at the moment we have any clear biomarker helping us to select who should not receive DLL3 T-cell engagers. Dr. Ece Cali: Those are great points and there is a lot we need to learn about how to use these novel agents in the future. I'd like to highlight the results in large cell neuroendocrine carcinoma of the lung. The response rate in this group was remarkably high at 70%. Though we should note the small sample size of only 14 patients in this trial. After first line chemoimmunotherapy, current approved options for this population have very modest clinical activity. Given these trial results, how do you envision the field moving forward for patients with large cell neuroendocrine carcinoma? Dr. Martin Wermke: Yeah, I think LCNEC is really an area which urgently needs further improvement of therapeutic standards. At the moment, as I said, there is no real standard. We are usually extrapolating from results we have in small cell lung cancer or non-small cell lung cancer, but I don't think we have too many prospective trials really informing this. Of course, 14 patients is a small sample size, but I think it's still fair to say that we can claim that DLL3 T-cell engagers are not doing worse in LCNEC than they do in SCLC. And that's why I think we really need to move forward clinical trials that are specifically targeting this population. Although I fear a bit that, given the rareness of this disease and the aggressiveness of its phenotype, that this is probably not the main focus of the pharmaceutical industry. So I think it's up to us academic investigators to really come up with investigator-initiated trials trying to fill the knowledge gaps we have here. Dr. Ece Cali: And one more thing that I want to talk about is the accessibility for these drugs. These novel agents are showing real promise in improving outcomes for patients with high-grade neuroendocrine tumors, an area where progress has been limited until very recently. However, as DLL3 BiTEs become more widely used, issues of logistics and access come into sharper focus. With unique toxicities and the specialized monitoring, their use is restricted to certain centers. Looking ahead, what kinds of strategies could help mitigate some of these adverse events or make these treatments more broadly available? Dr. Martin Wermke: Yeah, I think if you look at countries like the United States where tarlatamab has already been approved, we can see how the management strategies are evolving. I've heard about a colleague equipping their patients with thermometers and a pill of Dexamethasone, alongside with a temperature control protocol and clearly instructing them, "If you measure a temperature above a certain level then start taking the Dexamethasone and come back to our office and we're going to take care of you." I think that's one way to move forward. I think we are lucky in a way that CRS usually manifests within the first 24 hours. This was the same in our study, like in the tarlatamab studies. So we really know when the time of trouble is for our patients. And in this time, I think we need to instruct the patients to stay close to the hospital. I don't think we need to hospitalize all of them, but we probably need them to stay in a nearby hotel to be able to reach the emergency room if needed in a short period of time. And I think we can also learn in this strategy how to manage bispecific antibodies from the experience our colleagues in hematology had because they have been using bispecific T-cell engagers for quite some years right now and they developed strategies and networks that were able to successfully treat these patients also on an outpatient basis. And I think that is clearly an experience we need to follow, acknowledging that we are talking about diseases which are much more frequent than the standard hematology indications. Dr. Ece Cali: Thank you so much, Dr. Wermke, for this informative discussion and for sharing your perspective on this evolving field. Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to talk about data. It was really great being able to share that, and I really think that we are just at the beginning of a new exciting area for the treatment of neuroendocrine carcinomas, and I think much improvement is yet to come for our patients. Dr. Ece Cali: Yes, that's really exciting. And thank you everyone for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Martin Wermke's Disclosures Honoraria: Lilly, Boehringer Ingelheim, SYNLAB, Janssen, Merck Serono, GWT, Amgen, Novartis, Pfizer,  BMS GmbH & Co. KG, Regeneron, MJH/PER, Takeda Consulting or Advisory Role: Bristol-Myers Squib, Novartis, Lilly, Boehringer Ingelheim, ISA Pharmaceuticals, Amgen, immatics, Bayer, ImCheck therapeutics, AstraZeneca, Tacalyx, Regeneron, Daiichi Sankyo Europe GmbH, Zymeworks, PharmaMar, Iovance Biotherapeutics, T-Knife, Genentech Research Funding: Roche Patents, Royalties, Other Intellectual Property Travel, Accommodations, Expenses: Pfizer, Bristol-Myers Squibb, AstraZeneca,  Amgen,  GEMoaB, Sanofi/Aventis, immatics,  Merck Serono, Janssen Oncology, Iovance Biotherapeutics, Daiichi Sankyo Europe GmbH"

In this episode, Jack Cochran and Matthew James are joined by Art Fromm, author of "Making Seamless Sales" and sales enablement expert, to discuss how presales and sales teams can work together more effectively. Art shares insights from his 25+ years in sales enablement, exploring the common disconnects between SEs and AEs, and provides practical strategies for building stronger partnerships that drive better outcomes. The conversation covers the evolution from tribal knowledge to systematic collaboration, the importance of discovery before demos, and how to create value perception rather than just showing features. Art emphasizes that when teams work together properly versus teams that don't, there's a 37% difference in sales outcomes - a substantial opportunity sitting on the table. Connect with Us Connect with Jack Cochran: https://www.linkedin.com/in/jackcochran/ Connect with Matthew James: https://www.linkedin.com/in/matthewyoungjames/ Connect with Art Fromm: https://www.linkedin.com/in/artfromm/ Links and Resources Mentioned Join Presales Collective Slack: https://www.presalescollective.com/slack Art's Website: https://teamsalesdevelopment.com Team Sales Development: https://www.teamsalesdevelopment.com "Making Seamless Sales" by Art Fromm: https://teamsalesdevelopment.com/making-seamless-sales-book/ Timestamps 00:00 Welcome 03:55 Sol/Con East 2025 05:26 Making SEAMless Sales 11:27 Our Solutions Have No Value 24:02 You Only Get One Shot 29:42 Aren't We All Presales Key Topics Covered The SEAM Framework SE (Solutions Engineers) and AM (Account Managers) working together Breaking down organizational silos between presales and sales Creating systematic approaches rather than leaving collaboration to chance Moving Beyond the Demo Rush Why "we need to do a demo" often leads to failure The importance of proper qualification and discovery first How luck can reinforce bad habits in sales processes Creating Value Perception Understanding that solutions have no inherent value The Venn diagram of customer needs overlapping with solutions Turning "sell" into "buy" and "push" into "pull" The Trust Dynamic Presales comes with trust that can be lost Sales lacks trust that needs to be gained How proper discovery helps both teams build credibility Organizational Alignment Top-down (business focused) vs bottom-up (technical focused) approach Creating healthy overlap between sales and presales responsibilities The pyramid model of customer engagement levels Training and Enablement Moving beyond feature-function training to client success thinking Understanding the complete buyer journey from hello to consumption The concept of "solution enablement" as a continuous process

In this episode of the East Coast Elite series, we sit down with Madina Burkov, VP of Global Sales Development at Harness, to break down everything you need to know about starting a career in tech sales as a Sales Development Representative (SDR). Madina shares insights into the essential skills for success, how to assess if a company's SDR program is right for you, and the critical role SDRs play in generating pipeline and driving revenue. We also discuss practical advice on how to stand out during the application process, the importance of a growth mindset, and why the "gift of the gab" isn't the only path to a successful sales career.

Deux invités nous expliquent le rôle politique de l'opposition. Et comment il est possible de contester le pouvoir en place quand les partis sont interdits.

Software Demo Secrets That Instantly Close Deals – Struggling to move deals forward after group demos? In this video, sales expert Nick Cegelski reveals a proven software demo process that keeps prospects engaged and drives real buying conversations. Discover what elite sellers do before and after a demo to build trust, personalize the experience, and win over every key stakeholder. You'll learn why cold demos fail, how to warm up the room with pre-calls, and how post-demo follow-up can unlock true multithreading. Whether you're in SaaS sales, B2B tech, or enterprise deals, these software demo tips will help you close faster and more consistently. Perfect for AEs, SDRs, and anyone leading complex sales cycles. Stop winging your demos. Start winning them.

On Healthy Mind, Healthy Life, host Avik Chakraborty sits down with Dr. Shanea Clancy—international speaker, forensic nurse, business strategist, and #1 international bestselling author—to break down what it really takes to shift from a fixed mindset to a fearless, outcomes-driven culture. This direct, practical conversation covers limiting beliefs, imposter syndrome, burnout signals at the top, people-first leadership, measurable ROI from mindset work (retention, productivity, onboarding costs), and how to turn trauma into transformation without the fluff. If you lead a team—or you're rebuilding your own resilience—this episode gives you clear steps to diagnose hidden costs, reset boundaries, and build momentum that compounds across life and work.   About the guest  :   Dr. Shanea Clancy has addressed audiences of 65,000+, consulted for Fortune 500 companies, and shared stages with leaders like Jack Canfield and Jamie Kern Lima. Her approach integrates executive coaching, organizational consulting, and lived experience—translating mindset into concrete performance indicators across quality, safety, and culture.   Key takeaways  : Fixed mindset shows up as limits: persistent limiting beliefs, imposter syndrome, and unwillingness to consider other viewpoints—stalling innovation and trust. People > paperwork: SOPs and dashboards matter, but people systems determine performance. Neglect them and you pay in disengagement, sick days, and higher premiums. Hidden costs are measurable: watch AES scores, behavior-response metrics, retention, onboarding costs, and absenteeism to quantify culture gaps and ROI of leadership work. Burnout is silent and fast: leaders who try to “do it all” erode decision quality. Proactive boundary-setting, delegation, and recovery rituals reduce risk. Trauma → transformation is a process: anchor to purpose, tolerate uncertainty, and make micro-shifts; the goal is progress with fear—not the absence of it. Mindset isn't fluff: when leaders model clarity and recognition, teams align to goals, productivity rises, and attrition falls—strategy + mindset is the multiplier. Practical moves this week: run a quick people-health audit (listening cadence, recognition, recovery time), define top 3 KPIs per role, and set one non-negotiable boundary.   Connect with the guest   Connect with the Guest:Website: Dr. Shanea Clancy's WebsiteInstagram: https://www.instagram.com/shaneaclancyLinkedIn:https://www.linkedin.com/in/shanea-clancyAlso follow @clancyconsulting on social media.   Want to be a guest on Healthy Mind, Healthy Life?   DM on PM - Send me a message on PodMatch DM Me Here:https://www.podmatch.com/hostdetailpreview/avik   Disclaimer: This video is for educational and informational purposes only. The views expressed are the personal opinions of the guest and do not reflect the views of the host or Healthy Mind By Avik™️. We do not intend to harm, defame, or discredit any person, organization, brand, product, country, or profession mentioned. All third-party media used remain the property of their respective owners and are used under fair use for informational purposes. By watching, you acknowledge and accept this disclaimer.   Healthy Mind By Avik™️ is a global platform redefining mental health as a necessity, not a luxury. Born during the pandemic, it's become a sanctuary for healing, growth, and mindful living. Hosted by Avik Chakraborty—storyteller, survivor, wellness advocate—this channel shares powerful podcasts and soul-nurturing conversations on:• Mental Health & Emotional Well-being• Mindfulness & Spiritual Growth• Holistic Healing & Conscious Living• Trauma Recovery & Self-Empowerment With over 4,400+ episodes and 168.4K+ global listeners, join us as we unite voices, break stigma, and build a world where every story matters.Subscribe and be part of this healing journey.   ContactBrand: Healthy Mind By Avik™Email: join@healthymindbyavik.com | podcast@healthymindbyavik.comWebsite: www.healthymindbyavik.comBased in: India & USA Open to collaborations, guest appearances, coaching, and strategic partnerships. Let's connect to create a ripple effect of positivity.   CHECK PODCAST SHOWS & BE A GUEST:Listen to our 17 Podcast Shows: https://www.podbean.com/podcast-network/healthymindbyavikBe a guest on our other shows: https://www.healthymindbyavik.com/beaguestVideo Testimonial: https://www.healthymindbyavik.com/testimonialsJoin Our Guest & Listener Community: https://nas.io/healthymindSubscribe To Newsletter: https://healthymindbyavik.substack.com/   OUR SERVICESBusiness Podcast Management - https://ourofferings.healthymindbyavik.com/corporatepodcasting/Individual Podcast Management - https://ourofferings.healthymindbyavik.com/Podcasting/Share Your Story With World - https://ourofferings.healthymindbyavik.com/shareyourstory   STAY TUNED AND FOLLOW US!Medium - https://medium.com/@contentbyavikYouTube - https://www.youtube.com/@healthymindbyavikInstagram - https://www.instagram.com/healthyminds.pod/Facebook - https://www.facebook.com/podcast.healthymindLinkedIn Page - https://www.linkedin.com/company/healthymindbyavikLinkedIn - https://www.linkedin.com/in/avikchakrabortypodcaster/Twitter - https://twitter.com/podhealthclubPinterest - https://www.pinterest.com/Avikpodhealth/ SHARE YOUR REVIEWShare your Google Review - https://www.podpage.com/bizblend/reviews/new/Share a video Testimonial and it will be displayed on our website - https://famewall.healthymindbyavik.com/   Because every story matters and yours could be the one that lights the way!   #podmatch #healthymind #healthymindbyavik #wellness #HealthyMindByAvik #MentalHealthAwareness#comedypodcast #truecrimepodcast #historypodcast #startupspodcast #podcasthost #podcasttips #podcaststudio #podcastseries #podcastformentalhealth #podcastforentrepreneurs #podcastformoms #femalepodcasters #podcastcommunity #podcastgoals #podcastrecommendations #bestpodcast #podcastlovers #podcastersofinstagram #newpodcastalert #podcast #podcasting #podcastlife #podcasts #spotifypodcast #applepodcasts #podbean #podcastcommunity #podcastgoals #bestpodcast #podcastlovers #podcasthost #podcastseries #podcastforspeakers#StorytellingAsMedicine #PodcastLife #PersonalDevelopment #ConsciousLiving #GrowthMindset #MindfulnessMatters #VoicesOfUnity #InspirationDaily #podcast #podcasting #podcaster #podcastlife #podcastlove #podcastshow #podcastcommunity #newpodcast #podcastaddict #podcasthost #podcastepisode #podcastinglife #podrecommendation #wellnesspodcast #healthpodcast #mentalhealthpodcast #wellbeing #selfcare #mentalhealth #mindfulness #healthandwellness #wellnessjourney #mentalhealthmatters #mentalhealthawareness #healthandwellnesspodcast #fyp #foryou #foryoupage #viral #trending #tiktok #tiktokviral #explore #trendingvideo #youtube #motivation #inspiration #positivity #mindset #selflove #success

https://www.linkedin.com/in/christophkarger/https://www.linkedin.com/company/gotonetworkhttps://www.linkedin.com/in/sbretzler/summaryOutbound Conversion verdoppelt – Von Quantität zu Qualität: Wie Sarah ihr SDR-Team neu aufgestellt hat In dieser Folge von GoToNetwork spricht Christoph Karger mit Sarah Brezla von Lanes & Planes über einen der wichtigsten Hebel im modernen Software Sales: Relevanz statt Schlagzahl. Sarah beschreibt offen, wie sie ihre SDR-Organisation neu aufgesetzt hat – weg vom rein quantitativen Cold Outreach, hin zu einem qualitativ hochwertigen Prozess mit klarem Fokus auf den idealen Kunden. Der Wandel war tiefgreifend: neue KPIs, neues CRM, neue Rollenverteilung zwischen SDRs und AEs – und nicht zuletzt ein völlig neues Verständnis von Qualifizierung. Im Gespräch geht es um die Herausforderungen, die solche Veränderungen mit sich bringen, und wie man Teams durch diese Phasen begleitet – mit Enablement, externer Unterstützung und klarer Kommunikation.takeawaysSales erfordert sowohl Quantität als auch Qualität.Die Psychologie im Sales ähnelt der im Leistungssport.Konsistenz in der Basisarbeit ist entscheidend für den Erfolg.Veränderungen im Team müssen gut kommuniziert werden.Persönliche Kontakte sind entscheidend für die Konversion.Ein klar definiertes Zielbild ist wichtig für den Veränderungsprozess.Training und Enablement sind Schlüssel zum Erfolg.Externe Coaches können wertvolle Perspektiven bieten.Die Identifikation des idealen Kunden ist entscheidend.Qualität im Outreach kann die Effizienz steigern.Sound Bites"Wir müssen uns immer wieder neu finden.""Wir haben externen Coaches gearbeitet.""Das Zielbild muss klar kommuniziert werden."Chapters00:00Einführung in den qualitativen Outreach04:07Die unbequemste Wahrheit im Sales10:56Veränderungen im SDR-Team und deren Herausforderungen19:29Qualität im Sales-Prozess25:28Erfolgreiche Strategien für SDRs und AEs31:39Die Bedeutung von persönlichem Kontakt36:57Enablement und kontinuierliche Verbesserung45:20Abschluss und Ausblick

About Stevee Danielle:Stevee Danielle is the CEO of FiveCRM and BeePurple, leading transformation in addiction recovery technology after a remarkable journey from cosmetology through enterprise SaaS sales. Having experienced every level from individual contributor to C-suite across multiple industries, Stevee brings unique empathy and adaptability to her leadership role, where she's leading a mission-driven SaaS that helps recovery centers prove their impact through data.About BeePurple:BeePurple is a specialized CRM platform designed for addiction recovery centers, transforming how peer support specialists stay connected with people in recovery. Built on the principle that "connection beats addiction," the platform helps recovery centers track outcomes, manage relationships, and aggregate data to prove their community impact. Unlike traditional B2B SaaS, BeePurple serves clients who often still use pen and paper in their roles day-to-day, creating a unique approach to selling and supporting mission-driven technology.Show Notes:00:00 Introduction and Background: From cosmetology to SaaS leadership01:18 Transitioning to SaaS Sales: "The only thing I knew about software was I couldn't hold it"02:27 Building Relationships in Sales: How years as a cosmetologist prepared her for enterprise03:30 Selling a Technical Product: The discovery that led to pairing AEs with SEs06:45 Leadership and Team Dynamics: Learning to be receptive from early mentors12:06 From Individual Contributor to CEO: Taking empathy from every level of the journey15:02 Empathy in Leadership: "I wouldn't ask my team to do anything I haven't done"18:05 The Unique Value of BeePurple: Shifting from traditional B2B to mission-driven sales20:55 Connecting with Recovery Centers: Selling to heroes who aren't on LinkedIn

No episódio 171 do Outliers InfoMoney, Clara Sodré e Fabiano Cintra recebem uma das vozes mais respeitadas da economia brasileira: Armínio Fraga, ex-presidente do Banco Central do Brasil e sócio-fundador da Gávea Investimentos.Será que estamos caminhando para uma nova ordem global e um mundo “pós-dólar”? Como a estratégia de Javier Milei e os problemas fiscais da Argentina podem afetar a região? Bancos Centrais independentes estão sob ameaça? E o que esperar do Brasil diante da inflação, do câmbio, dos juros elevados e das eleições de 2026? Esses são alguns dos temas desta conversa exclusiva com um dos oráculos do mercado financeiro. Entre projeções para o futuro e reflexões pessoais, Armínio compartilha uma visão única sobre os desafios e as oportunidades que moldam o Brasil e o mundo. Confira este episódio de colecionador do Outliers InfoMoney!

In deze aflevering praat ik met Vladan Soldat over het nieuwe Sales Benchmark Report (330 respondenten uit NL, DACH en Nordics). We hebben het over OTE-structuren, waarom een VP Sales soms meer verdient dan een CRO, targets die motiveren, de opkomst van de GTM Engineer en waarom AI-SDR's (nog) geen vervangers zijn. Praktische inzichten voor founders en salesleaders. Belangrijkste inzichten • VP vs. CRO: het basisloon van een CRO ligt hoger, maar de OTE van een VP Sales vaak nog hoger door focus op new business. • Compensatie groeit mee met revenue stage: duidelijke lijn van seed tot 50M+ ARR. • Wat talent écht waardeert: flexibiliteit, mobiliteit en equity (vooral AEs) naast salaris. • Regionale verschillen: Nordics presteren boven target, terwijl Nederlandse reps gemiddeld meer verdienen maar minder attainment halen. • Quota-filosofie: targets moeten stretchen maar niet breken – anders demotiveren ze. • BDR-carrièrepad: niet alleen AE, maar ook richting Senior/Manager of de opkomende rol van GTM Engineer. • AI-SDR: volledige vervanging werkt niet, maar tooling voor enablement maakt nu wel verschil. • Eerste sales hire: reken op ~70–80% van de founder-output in jaar 1. • Overperformance: beloon uitzonderlijke resultaten met accelerators en spiffs. • Europa uitrollen: kopieer comp & targets niet klakkeloos; lokale context is bepalend. Topics die we bespreken • Hoe het benchmarkrapport tot stand kwam (2019 → nu) • Marktwerking vs. “gelijke monniken, gelijke kappen” bij comp • Target setting in early stage en de rol van pipeline-KPI's • Equity als hefboom voor startups in de war on talent • AI en sales: hype vs. realiteit • Lokalisatie van salary bands bij internationale expansie Takeaways voor founders 1. Definieer wat je wilt stimuleren – en plak daar een spiff of kicker op. 2. Houd targets haalbaar maar uitdagend; evalueer ze regelmatig. 3. Compete beyond cash – cultuur, flexibiliteit en equity zijn doorslaggevend tegen Big Tech. 4. Maak BDR's tot een talentpool; denk breder dan alleen AE. 5. Lokale realiteit eerst bij Europese expansie. Quote van Vladan “Het OTE van een VP Sales ligt vaak hoger dan dat van een CRO – omdat nieuw ARR simpelweg harder wordt beloond dan het managen van de totale revenue-huishouding.” Links •

As ações da Pop Mart, fabricante dos conhecidos Labubu, caíram quase 9% no arranque da sessão desta segunda-feira, em Hong Kong, mas reduziram as perdas ao longo do dia tendo terminado com uma desvalorização de 6,4%See omnystudio.com/listener for privacy information.

The governor stops by to remember 9/11, discuss the assassination of Charlie Kirk, AES fight, and more. See omnystudio.com/listener for privacy information.

Rob from Kendall and Casey joins to talk AES, datacenters moving in, and more. See omnystudio.com/listener for privacy information.

Host Dr. Shannon Westin and guest Dr. Hani Babiker discuss the JCO article "Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." TRANSCRIPT TTFields in Locally Advanced Pancreatic Adenocarcinoma Dr. Shannon Westin: Hello everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth with manuscripts that have been published in the Journal of Clinical Oncology. I am your host, gynecologic oncologist Shannon Westin, social media editor at the JCO, and just excited to be here to learn today about pancreatic cancer. None of our participants have conflicts of interest related to this podcast, and it is my honor to introduce Dr. Hani Babiker. He is an associate professor of medicine, consultant in oncology at the Mayo Clinic in Jacksonville, Florida. Welcome, Dr. Babiker. Dr. Hani Babiker: Hi, Dr. Westin. Thank you for the great opportunity to discuss our trial, and thank you for having me here. I really appreciate it, and I am excited. Dr. Shannon Westin: All right, so are we. So we are going to be talking about “Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.” This was simultaneously published and presented in the JCO and at the annual meeting of ASCO on 5/31/2025. So, let's level set. Can you speak to us just a little bit about pancreatic cancer? What is the survival, and what is the typical treatment for locally advanced disease? This gynecologic oncologist has not kept up in this field. Dr. Hani Babiker: Absolutely, Dr. Westin, and thank you for that question. Pancreatic adenocarcinoma is a lethal cancer. When I first started my career, the 5-year survival, per the Surveillance, Epidemiology, and End Results, was at 4.5%. I always, whenever I was giving talks, say that I really hope that I will see it in the double digit. Now, the 5-year survival for all pancreatic adenocarcinoma is 13.3%. And the 5-year survival, and although it is a double digit, I still hope that I will see it in a higher double digit in the future. It is even worse in patients with metastatic cancer, about 3% 5-year survival for metastatic pancreatic cancer. It is a dismal diagnosis. I really hope in the future we will find a better therapeutic approach to this lethal cancer. Dr. Shannon Westin: Yes, I just lost a very dear friend and colleague to this disease, so I completely agree with you. Well, now that we are settled kind of with the basics here, I would love to talk a little bit about kind of the primary piece of this intervention, the Tumor Treating Fields. So, how does this work? And what diseases has it gotten indications in as yet? Dr. Hani Babiker: Absolutely. So, Tumor Treating Fields is alternating frequency electrical fields that have been studied preclinically and shown that it abrogates cancer cell proliferation. Earlier on, we knew that it inhibits polymerization of tubulin, and hence, it affects cancer cells from proliferating. Later, we are learning that there are multiple mechanisms of action. It affects permeability, allowing for better drug delivery. It also inhibits cancer cell proliferation through affecting autophagy mechanisms that pancreatic cancer cells will use for proliferating and becoming more aggressive. There is also some early data preclinically in colorectal cancer cell lines and lung cancer cell lines and in vivo models showing that it potentially could activate the microenvironment to make it more pro-immunogenic. We recently published papers showing that it could also affect the nanomechanical properties of the tumor microenvironment within pancreatic cancer, hinting towards affecting, potentially, the stroma. So, there are multiple mechanisms to Tumor Treating Electric Fields. It is a new, novel therapeutic approach. Sometimes when I speak with my trainees, I say, "Well, we have surgery, we have radiation and chemotherapy, and this is something new." Tumor Treating Fields initially was studied in refractory GBM and got an indication there. Subsequently, frontline treatment of GBM in a randomized clinical trial, and then malignant pleural mesothelioma and non-small cell lung cancer. We have studied it in pancreatic cancer. Dr. Shannon Westin: I don't think I have ever heard it described so perfectly. That was brilliant. So thank you, and I hope everyone listening knows that you just got a masterclass on this mechanism. You know, they dabbled in it a little bit in ovarian cancer and it didn't quite make the grade, so I was a little definitely disappointed. But very excited about the data we're going to talk about today. So let's get into the PANOVA-3 study. Can you highlight the overall design and also the key eligibility criteria that would be helpful for our listeners? Dr. Hani Babiker: Absolutely. So, it started off with preclinical work in pancreatic cancer showing Tumor Treating Fields with chemo abrogate cancer cell perforation. It led to a trial, the PANOVA-2 trial, that was run in Europe that showed efficacy for OS and PFS in patients with locally advanced pancreatic cancer, which included metastatic and locally advanced pancreatic cancer, more so in locally advanced that led to the PANOVA-3 trial, which was an international, global study. This was in more than 190 centers, 20 countries in Latin America, North America, Europe, and Asia. It was a randomized trial. Patients were randomized 1 to 1 to either chemotherapy with gemcitabine plus nab-paclitaxel per drug label. The other arm was with Tumor Treating Fields at 150 kHz for a recommendation for patients to wear it 18 hours per day. The primary end point of the trial was OS, overall survival. The secondary end point included other efficacy landmarks such as local PFS, pain control, quality of life, and safety. And there was a post hoc that looked at distant PFS. Dr. Shannon Westin: That's a pretty common secondary end point in pancreatic studies of looking at the pain-free interval. I thought that was really brilliant because, you know, I think in gyn cancers, we see resolution of symptoms as being a really big deal, but it's not necessarily something that we always look at. So I thought that was really nice that you included that. Okay, talk to us a little bit about the population. So, the population that actually got treated in PANOVA-3 is pretty generalizable to what people are treating in the clinic. Dr. Hani Babiker: So, in pancreatic cancer, unfortunately, most of our patients present, approximately 80%, with metastatic disease. Local is divided to resectable, borderline, and locally advanced. We studied this trial, a randomized trial, in locally advanced and unresectable, which is really an unmet need. Most of our patients with locally advanced and unresectable are grouped up with other trials in the metastatic setting without a focus on locally advanced and unresectable, save for a few trials. This year, a trial that we were looking for for a long time, the LAPLACE trial, unfortunately, that we were very excited about, this is a molecule that targeted connective tissue growth factor, that showed earlier efficacy in a randomized trial, did not meet up the median OS end point. And hence, PANOVA-3 is the first trial in locally advanced and unresectable that did meet its primary end point. So, it's a very unmet need in locally advanced and unresectable. A lot of the times, our patients in clinic are treated with frontline chemotherapy that was studied in metastatic disease and locally advanced and unresectable, which include either FOLFIRINOX, NALIRIFOX, or gemcitabine/abraxane. I do have in my clinic multiple patients that would stay on the regimen for such a long time, and then we would have to devise a mechanism of maintenance, although this is not studied really in details, either with capecitabine or dropping the oxaliplatin to continue FOLFIRI. And then we also approach chemoradiotherapy. So the trial was in a disease in pancreatic cancer that really is an unmet need. So the inclusion criteria included a patient with locally advanced and unresectable. These were done at multiple centers. Most of them academic centers were discussed at the tumor board, and if it's unresectable, they will be meeting specific metrics of appropriate liver function tests, kidney function tests, and blood counts. We excluded patients that obviously had, given that these are electric fields, patients that have, for example, stimulators or pacemakers, knowing that this could potentially affect some of these devices. But for the most part, it was locally advanced and unresectable patients with a very good performance status and good counts. Dr. Shannon Westin: That's great. I think everyone's excited to hear about the primary outcome of overall survival. What did you find, and how does it compare to some of the recent trials? Dr. Hani Babiker: We're very excited that it did meet its primary end point of median overall survival. It was very exciting knowing that a lot of us were disappointed a little bit of some of the trials that were presented at ASCO GI, such as the LAPLACE trial that I alluded to. Just before the presentation, the PRODIGE 29 trial that is in locally advanced and unresectable that randomized patients with locally advanced disease to either FOLFIRINOX or single-agent gemcitabine, allowing for a crossover, although it did meet its primary end point of PFS, there was no overall survival benefit. So that kind of got us a little bit disappointed, but having the PANOVA-3 trial being positive in median OS got us all excited. In addition, the 12-year overall survival rate was increased in both the intention-to-treat and modified intention-to-treat. The modified intention-to-treat were patients that have had at least one cycle of therapy with TTFields daily and/or one cycle with chemotherapy, which was gemcitabine plus nab-paclitaxel. There was a trend to improvement in PFS and local PFS, although that did not have statistical significance, but the 12-year PFS rate in both the intention-to-treat and modified intention-to-treat was significant. For me, as one of the investigators, that told me that there might be a specific biomarker that would tell me that patients could respond greater than others, more exceptional than others, given that 12-month PFS rate was improved. On a post hoc analysis, the distant PFS was improved with the intervention of Tumor Treating Fields with gemcitabine plus nab-paclitaxel. In addition, there was an improvement in global health status and quality of life in addition to pain-free survival, which is a strong hurdle in our patients with pancreatic adenocarcinoma that most present with significant abdominal pain. Dr. Shannon Westin: One of the other questions that I think has come up is around central review. So did you all use central review in this study? Dr. Hani Babiker: Most of the centers were academic centers. These were discussed in tumor boards, which included radiation oncologists and surgeons. I wanted to point out that it's very important to note that the primary end point was overall survival. So the primary end point was not PFS. Hence, the central review would help us, for example, with elaborating and making sure patients were actually locally advanced disease, but in a setting where the primary end point is overall survival, that was the key point of the clinical trial. This trial was discussed at academic centers, and all included tumor boards to decide if patients were locally advanced or not. In the trial, there was a good proportion of patients, or percentage, that had a CA 19-9 more than 1000. That could indicate that potentially there are a fraction of patients that actually had metastatic disease, micrometastatic disease. So that could hint towards why the median OS was slightly lower then in both arms when compared to, for example, the trial that was presented at ASCO GI, the LAPLACE trial. However, having said that, we were very excited about the trial. It was the first positive trial in locally advanced and unresectable to meet median OS survival. Dr. Shannon Westin: It's so awesome. So congratulations. Okay, so let's talk a little bit about your very detailed secondary end points because you had a lot of really prudent choices there. So anything that was interesting or informative in those end points? Dr. Hani Babiker: One major hurdle back we have for most of our patients with pancreatic adenocarcinoma, like I mentioned earlier, is pain. We try to approach it, obviously, with narcotics. If it doesn't work, we try to do celiac axis block interventionally, and that sometimes is successful and sometimes is not. So actually, to see the pain-free survival end point to be met was very exciting for us. And as for me, as a scientist that studies TTFields in clinic and lab as also to develop a mechanism and understanding really how that works. That was very important for us that in addition to chemotherapy, it improved pain-free survival or deterioration of pain. And most importantly, our patients with pancreatic cancer, this disease is very aggressive. It affects quality of life of patients. Patients feel fatigued, tired. It's a procoagulant tumor that causes clots and strokes, etcetera, marantic endocarditis. And one big problem we deal with when we're seeing patients in clinic is obviously that quality of life. Although data have shown with treatment, with frontline regimens, that quality of life improves with treatment and chemotherapy, it's actually great to see that that improvement happens early in addition to Tumor Treating Fields. The other interesting point was that it was not only pain and quality of life, but also digestive symptoms that are improved with this intervention, knowing that a lot of our patients do have pancreatic cancer, pancreatic exocrine insufficiency that affect also with digestion, and a lot of our patients have abdominal pain after eating and diarrhea. So it was interesting to see that also improved with the intervention. Dr. Shannon Westin: You have touched a little bit on some of the adverse events, kind of with the TT mechanisms, but I'd love to hear a little bit more detail around adverse events in general in this study, as well as specific AEs related to the Tumor Treating Fields. Dr. Hani Babiker: Absolutely. So when we compared both arms, there was a similar toxicity related to the regimen, mostly with chemotherapy, but in specifically to Tumor Treating Fields, there was a rash, and that included dermatitis and rash. Most of the side effects were grade 1 and grade 2. Grade 3 toxicities related to skin was less than 10%, approximately 7% to 8%, and hence did not affect many patients. But it was something to note, and it's something that in the future, when we develop a mechanism of treating patients to note early. We in our clinic have learned to treat patients in the clinical trial early with topical steroids to each patient, of shifting the arrays to mitigate some toxicity and rash. We do advise our patients in hot areas, we keep them aware that sweating, for example, can lead to higher conductivity of electrical fields with a predisposition for rash. So if there's an opportunity to stay in a little bit of a cold area, make sure that the arrays are shifted, use topical steroids early. If it's a significant rash, to hold treatment for at least 48 hours and speak to the investigators. And through these mechanisms, we have learned that we were able to mitigate the rash quite a bit. Dr. Shannon Westin: That's awesome. Thank you so much. Yeah, I'm, it's summer right now, and I think- I'm in Texas, you're in Florida, like we know. Okay, so I guess, again, you have been kind of touching on this, but I would love to know, like if in the quality-of-life assessments or if just in your discussions with patients, like how easy is this to use? How easy is the Tumor Treating Fields device to use, and what do patients really think? Dr. Hani Babiker: Absolutely. We have learned that whenever we speak with patients, it's always good to discuss with them briefly the science of it. A lot of patients would want to know if it's interventional, is that something that goes, is delivered percutaneously or not, and we explain that these are delivered through arrays that are through the skin. We always touch base with them about a lot of question I get about mechanism of action and then about compliance. So I think one important thing to note is that compliance with the use of the device is a lot of the question we'll get quite a bit. Patients know there's going to take an effort from them, and some of my patients enjoyed it because they felt like they also are fighting the disease by wearing the device. I have learned very quickly that having a team, surrounded by a team that knew how to mitigate some of the side effects and knew how to explain how to use the device helped quite a bit. And this included some of our nurses and our nurse practitioners and our clinical research coordinators who've done a wonderful job of showing these arrays actually to patients before they start on the trial, look at it, know how it works. The other point to know is that the sponsor provided Device Support Specialist, we call them DSS, they have been instrumental in helping us, helping the patients know how to use the device, how to use the generator, how to change the batteries, and that helped us conduct the trials and enroll very well. I would envision in the future with education and relying on the Device Support Specialist and having a team that knows how to use the device and mitigate some of the side effects will go a long way for patients to learn about this treatment. Many of the times our patients said while they are on the clinical trial felt like they are also being part of this team in applying the device and fighting the cancer. Dr. Shannon Westin: That's awesome. Well, I guess the bottom line. Is it ready for prime time? Is this something you are going to use for your patients in the clinic? Dr. Hani Babiker: Absolutely. In a disease that has poor prognosis, and we are trying our best to find new treatments to fight this cancer and treatment modalities, presenting patients with all the treatment options that are out there would be recommended. It's what I would do it for in my clinic. And you know, it's funny that I am mentioning that right now. I had a patient who was seen internationally asking about the trial and the device and had locally advanced and unresectable before they start frontline treatment. I do think that there is going to be an educational piece. Obviously, this is not a pill, it's not an intravenous chemotherapy that we're very well and accustomed to. And some of us in academic centers know it very well. I usually joke that whenever I am talking about it in pancreatic cancer, if there is a radiation oncologist in the room, they will be like, "Yeah, we know all about it. We have been treating patients with GBM over there." So a lot of the times, when we first went to trial, if I had any questions, I would call them and ask them. So from their perspective, they, because they use it as a standard of care in treatment of GBM, they develop significant expertise in it. I think in the GI world, specifically and with oncologists that treat pancreatic cancer and specifically oncologists in the community, learning about the device and how to use it, how to recommend it, how to mitigate side effects, will be hopefully for prime time in the future. Dr. Shannon Westin: That's great. Sounds like some real educational opportunities there. Well, this has been awesome. Thank you so much, Dr. Babiker. I mean, I learned a ton, and I wish that we could find a way to use this in gynecologic cancers, but really, really just want to commend you on the design of the trial and the success in this really devastating disease. So again, this was "Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." And as always, I am your host, Shannon Westin. Please go check out our other offerings wherever you get your podcasts and have an awesome day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Dr. Babiker Disclosures Consulting or Advisory Role: Endocyte, Celgene, Idera, Myovant Sciences, Novocure, Ipsen, Caris MPI, Incyte, Guardant Health Speakers' Bureau: Guardant Health Research Funding:  Spirita Oncology, Novocure, AstraZeneca, JSI, Incyte, Qurient, HiFiBiO Therapeutics, Revolution Health Care, Elevation Oncology, Dragonfly Therapeutics, Zelbio, BMS, Mirati Therapeutics, Strategia        

In the second episode of Season 15, Tim sits down with "Montana" Dave Anderson from AES to follow up on last week's conversation with Clay Dennis about how intentional small dollar sales can lead to big time growth in your business. Tim and Dave Discuss: Dealers and manufactures feeling sales pressure in the coming season, years after the post-pandemic boom. Listening well to customer's problems in order to offer effective solutions. Not letting opinions or assumptions about products or customers keep you from making a sale. Following a checklist of items to maximize small dollars that add up to big sales. Don't miss this great conversation to hear how the steps that increase small sales can also lead to building an impactful business. ------ Become a supporter of The Fire Time Network and get access to awesome rewards: ⁠⁠https://itsfiretime.com/join⁠⁠ To hear more audio articles from our magazine, subscribe to the Fire Time Magazine Podcast: ⁠⁠https://www.itsfiretime.com/magazine⁠⁠ Read The Fire Time Magazine Reader Edition online: ⁠⁠https://magazine.itsfiretime.com⁠⁠ Download The Fire Time Magazine app to get full access to the magazine (for free): ⁠⁠https://www.itsfiretime.com/app

Hart joined the show to talk about Republicans voting to remove him as minority leader, why the safety committee ended downtown curfew discussion, AES plans to increase rates, and more.See omnystudio.com/listener for privacy information.

In this episode, Jack Cochran and Matthew James are joined by Akash Ganapathi, CEO of Opine, to discuss how AI strategies differ between startups and enterprises in the presales space. They explore the myth of AI replacing SEs, the importance of specialization vs. generalization, and how AI can help presales teams manage more revenue per team member while focusing on strategic, relationship-building activities. Follow Us Connect with Jack Cochran: https://www.linkedin.com/in/jackcochran/ Connect with Matthew James: https://www.linkedin.com/in/matthewyoungjames/ Connect with Akash Ganapathi: https://www.linkedin.com/in/akash-ganapathi/  Links and Resources Mentioned Join Presales Collective Slack: https://www.presalescollective.com/slack Opine: https://tryopine.com/ Contact Akash directly: akash@tryopine.com Timestamps 00:00 Welcome 04:35 Why AI strategy differs for startups vs enterprises 09:27 Debunking the myth of AI replacing SEs 18:35 The human element in buying and selling 24:35 How enterprises can leverage existing knowledge bases 28:12 The paradox of considering AI for every task 32:14 Future predictions for 2026-2027 Key Topics Covered Startup vs Enterprise AI Strategy Startups benefit from generalist approaches and bottom-up experimentation Enterprises need specialized, top-down AI strategies to avoid redundancy The role of specialization vs wearing multiple hats The AI Replacement Myth Why the "AI SE" that replaces human SEs doesn't work SEs do much more than just answer technical questions The importance of relationship building and strategic thinking Current AI Limitations Context window constraints (around 1 million tokens currently) Retrieval Augmented Generation (RAG) accuracy at ~75% Why breakthrough improvements are needed for true automation The Future of Presales with AI More revenue managed per team member Shift toward hiring less experienced SEs with AI enablement Focus on strategic consulting rather than administrative tasks Practical AI Implementation Draft-and-approve workflows for deliverables Automating account research, meeting prep, and RFP responses Using AI for onboarding and knowledge enablement Mid-Market Recommendations Lean toward enterprise-style, forward-looking strategies Enable not just current team but future hires Focus on cross-organizational enablement (AEs, product, marketing)  

#278 Content | In this episode, Dave brings together five B2B marketers who aren't just talking about AI, they're actually using it to change how their teams work. Each finalist from the Exit Five x Walnut AI Sessions takes the (virtual) stage to demo their workflow, share results, and answer questions from the judges.Here's what you'll hear:Jillian Hoefer's “content concierge” GPT trained on proprietary research to surface stats, quotes, and data for blogs, sales decks, and thought leadershipJake Heap's workflow using Meshy + VEO 3 to turn a simple mascot into animated 3D brand characters in minutesJessica Lytle's no-code ROI calculator built in Lovable that sales reps now run live on calls to build business casesUgi Djuric's high-volume content engine that scrapes industry news and sales call transcripts, then uses AI to summarize, generate content ideas, and even score leadsAnton Ruis' AI-powered buyer brief builder that pulls real-time economic data and tailors sales messaging to specific personasIt's part workshop, part competition, and packed with creative, tactical ways to put AI to work in B2B marketing today.Timestamps(00:00) - – Dave kicks off in a tux (02:44) - – Record-breaking registrations (03:22) - – Meet the judges: Benny & Jess (08:10) - – Jillian's “victim of repurposing” intro (08:50) - – Building a “content concierge” GPT from research data (10:14) - – Injecting stats + quotes into blogs and decks (14:10) - – How one report fueled 9+ months of content (19:10) - – Jake on bringing AI into marketing ops (20:33) - – Turning a mascot into a 3D character with Meshy (21:18) - – Animating it in VEO 3 (no designer needed) (24:33) - – Cutting animation time from weeks to minutes (30:32) - – Jessica builds a no-code ROI calculator in Lovable (33:41) - – AEs use it live on sales calls (34:25) - – Adding benchmarks + transparency to ROI math (41:43) - – Ugi's AI engine scrapes + summarizes industry news (44:00) - – Training custom GPTs on expert insights (50:40) - – Anton's real-time buyer briefs from economic data (53:15) - – Tailoring briefs for CROs, enablement, PMMs (56:59) - – Judges crown the winning use case + Dave's wrap-up Send guest pitches and ideas to hi@exitfive.comJoin the Exit Five Newsletter here: https://www.exitfive.com/newsletterCheck out the Exit Five job board: https://jobs.exitfive.com/Become an Exit Five member: https://community.exitfive.com/checkout/exit-five-membership***This episode of the Exit Five podcast is brought to you by Qualified.AI is the hottest topic in marketing right now. And one thing we hear a lot of you marketers talking about is how you can use AI Agents to help run your marketing machine.That's where Qualifed comes in with Piper, their AI SDR agent.Piper is the #1 AI SDR Agent on the market according to G2, and hundreds of companies like Box, Asana, and Brex, have hired Piper to autonomously grow inbound pipeline. How good does that sound?Qualified customers are seeing a massive business impact with Piper: a 3X increase in meetings booked and a 2X increase in pipeline.The Agentic Marketing era has arrived. And if you're a B2B marketing leader looking to scale pipeline generation, Piper the #1 AI SDR Agent is here to help.Hire Piper, the #1 AI SDR Agent, and grow your pipeline today.You can learn more at qualified.com/exit5

In a recent episode of the Oncology-on-the-Go podcast in collaboration with the American Psychosocial Oncology Society (APOS), host Daniel C. McFarland, DO, was joined by Christian J. Nelson, PhD, to discuss the often-overlooked subject of sexual health issues for men after cancer treatment. The discussion emphasized the importance of a nuanced approach to men's health, particularly in the context of genitourinary cancers like prostate and testicular cancer. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer in addition to being the psycho-oncology editorial advisory board member for the journal ONCOLOGY®. He opened the conversation by highlighting that while cancer's physical effects are well-documented, the mental and emotional toll is equally significant and often underappreciated in male patients. He highlighted that the field of psycho-oncology, which began with breast cancer, is now expanding to address men's specific needs. Men, he noted, are less likely to seek mental health support, yet have a higher risk of suicide, particularly at key moments in their cancer journey like diagnosis and recurrence. Nelson, chief of Psychiatry Service, attending psychologist, and codirector of the Psycho-Oncology of Care and Aging Program at Memorial Sloan Kettering Cancer Center, underscored that cancer treatments, especially for prostate cancer, often have profound adverse effects (AEs) that impact a man's sense of self and masculinity.  He detailed the effects of radical pelvic treatments and androgen deprivation therapy (ADT), which can lead to urinary incontinence, erectile dysfunction, and changes in sexual function and body image. These AEs can lead to feelings of being "broken," "inadequate," or "deflated." The pair discussed the "double-edged sword" of normalizing cancer, where patients are told their prognosis is good but are left unprepared for the life-altering AEs. This can lead to a sense of cognitive dissonance and isolation. The conversation stressed the need for clinicians to proactively normalize discussions about sexual health, making it clear that these are standard and expected aspects of the cancer experience. Both clinicians suggested that establishing a trusting relationship with patients is paramount and that referrals to psycho-oncology should be framed as an essential, not optional, component of treatment. They also recommend that clinicians consistently check in with their male patients about emotional and sexual well-being, even long after treatment has ended, to ensure they're coping with the lasting impacts of their experience. 

This week's episode of The Hydrogen Podcast takes you across North America and beyond, spotlighting where hydrogen is advancing—and where it's hitting hard roadblocks.

This week, Jeff Clark, former Forrester analyst and now Principal Analyst at Cleantech Insiders, is back from vacation, and he and our host Ian Truscott pull five f'in' things that caught his eye from the Norwest B2B Sales & Marketing Benchmark Report that they first talked about in their budgeting discussion in episode 280.  The five discussion points: Sales cycles are getting longer The pressure for buyer urgency Teach your AEs well The pressure is on product marketing The AI revolution is here As always, we welcome your feedback. If you have a suggestion for a topic that's hot for you that we should discuss, please get in touch using the links below. Enjoy! — The Links The people: Ian Truscott on LinkedIn and Bluesky Jeff Clark on LinkedIn Mentioned this week: B2B Sales & Marketing Benchmark Report: Results Revealed - Norwest Ian's column - Tuesday 2¢ - Why Now? Jeff's firm - Cleantech Insiders Ian's firm - Velocity B Rockstar CMO: The Beat Newsletter that we send every Monday Rockstar CMO on the web, Twitter, and LinkedIn Previous episodes and all the show notes: Rockstar CMO FM. Track List: Stienski & Mass Media - We'll be right back Remember The Name (Official Video) - Fort Minor You can listen to this on all good podcast platforms, like Apple, Amazon, and Spotify. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 5 of our series covers always-on encryption, the smart use of metadata, and our DIY install/repair/upgrade approach. Pure's approach to security is to have it built-in and non-optional, with end-to-end encryption—covering both user data and metadata—using device or software-based AES-256 alongside features like Rapid Data Locking, role-based access controls, and secure erasure methods to protect against breaches and support compliance needs. Next, hear about how metadata serves as the “secret sauce” for Pure, enabling highly efficient, granular data services and powering capabilities like snapshots and instant cloning through a scalable, multi-tiered framework that writes, caches, and protects metadata in ways traditional arrays cannot match. Finally, we touch on installation, repairs, and upgrades which are designed for ultimate simplicity and DIY ease, with non-disruptive software and hardware changes—thanks to Pure's Evergreen architecture—which allows organizations to grow and evolve storage resources without operational downtime, complex migrations, or compromise. These architectural choices underpin Pure's promise of secure, resilient, and agile storage that adapts to changing business needs while remaining effortless to manage. Series Overview: Pure Storage's foundational approach to product engineering is guided by 15 architectural decisions that were established at the company's inception and have shaped both the technical and user experience across its product lines. These architectural choices were not made arbitrarily—they stem from a deliberate focus on simplicity, efficiency, and scalability, ensuring Pure could deliver storage solutions that break away from legacy complexity and enable continuous innovation without compromise. This series will guide viewers through all of the 15 principles, helping you understand why certain choices were made, how they impact your operations, and how they compare to other industry features and products. Join Pure Report podcast hosts Rob Ludeman, Andrew Miller, and J.D Wallace for this fun technical retrospective on Pure Storage.

André Christ, Gründer von LeanIX, spricht über effektiven Enterprise Sales für komplexe Produkte. Er teilt, wie sie AEs zu Produktexperten entwickeln, warum schnelle Demos entscheidend sind und wie man Legacy-Anbieter erfolgreich ablöst. Was du lernst: Wie du technische AEs entwickelst Die richtige Demo-Strategie Den Unterschied zwischen Excel- und Legacy-Ablösung Warum Produktverständnis entscheidend ist ALLES ZU UNICORN BAKERY: https://zez.am/unicornbakery  Mehr zu André: LinkedIn: https://www.linkedin.com/in/andrechrist/  Website: https://www.leanix.net/de/  Mehr zu Florian: Florian Dostert: https://www.linkedin.com/in/florian-dostert/  Syntinels: https://www.syntinels.com/  Join our Founder Tactics Newsletter: 2x die Woche bekommst du die Taktiken der besten Gründer der Welt direkt ins Postfach: https://www.tactics.unicornbakery.de/ 

Send us a textCheck us out at:  https://www.cisspcybertraining.com Get access to 360 FREE CISSP Questions:  https://www.cisspcybertraining.com/offers/dzHKVcDB/checkoutGet access to my FREE CISSP Self-Study Essentials Videos:  https://www.cisspcybertraining.com/offers/KzBKKouvA catastrophic data loss incident involving South Yorkshire Police serves as a powerful security lesson in today's episode. We examine how 96,174 pieces of body-worn video evidence vanished during an IT upgrade, affecting 126 criminal cases. This real-world security failure highlights the critical importance of proper data management, backups, and third-party oversight—fundamental concepts that directly apply to your CISSP exam preparation.The heart of this episode tackles five challenging CISSP exam questions spanning multiple security domains. We methodically work through complex scenarios involving encryption algorithm selection, mitigating Single Sign-On risks in healthcare environments, containing Advanced Persistent Threats, addressing cross-border data protection compliance, and handling SQL injection vulnerabilities in government applications.For each question, I break down the critical thinking process that helps you eliminate incorrect answers and identify the best solution. You'll understand why AES-256 balances security and performance for financial data, how multi-factor authentication strengthens SSO implementations, when network segmentation becomes crucial for APT containment, why Data Loss Prevention systems address insider threats, and the importance of parameterized queries in secure software development.This episode demonstrates how to approach scenario-based questions methodically, turning what seems overwhelming into manageable decision points. By breaking down complex questions step-by-step, you dramatically improve your chances of success on the CISSP exam while building practical security knowledge that translates directly to real-world challenges.Visit CISSP Cyber Training for more resources, including 360 free practice questions to accelerate your certification journey. Remember, a methodical approach to security problems is your path to passing the CISSP exam the first time.Support the showGain exclusive access to 360 FREE CISSP Practice Questions delivered directly to your inbox! Sign up at FreeCISSPQuestions.com and receive 30 expertly crafted practice questions every 15 days for the next 6 months—completely free! Don't miss this valuable opportunity to strengthen your CISSP exam preparation and boost your chances of certification success. Join now and start your journey toward CISSP mastery today!

Master client engagement and outbound sales with special guest Chris Bussing, a seasoned sales expert with a wealth of experience from Google and Oracle. Listen in as Chris shares his compelling journey of transforming cold calls into warm relationships. Mark and Chris explore the art of thorough preparation and strategic research, understanding why clients might switch from competitors, and how aligning your pitch with their current initiatives can make all the difference. With an emphasis on intention, mindset, and tone, Chris explains how acknowledging objections rather than resisting them can turn a single connection into a career-defining opportunity. Learn how reaching out to various personas, from C-level executives to end users, can strengthen messaging and improve follow-up strategies. Additionally, discover the power of momentum bias, using countdowns for psychological wins, and the value of thoughtful engagement on LinkedIn.

Lij Shaw of Recording Studio Rockstars recently sat down with Gabe Dagrezio to dive into his journey from frontman of The New Story to a highly regarded producer, engineer, and studio owner. With years of experience in the music industry, Gabe has worked with a wide range of artists, helping them craft their sound through both performance and technical mastery. He emphasizes the importance of authentic recordings combined with solid technical skills, often sharing how preparation and understanding the artist's vision are key to great results. Gabe also talks about his studio setup, his approach to mixing and mastering, and how modern tools like room simulation headphones can elevate home recordings. Throughout the conversation, he highlights the value of community organizations like AES, continual learning, and building genuine relationships—lessons that are crucial for anyone looking to thrive in today's ever-changing industry. Get access to FREE mixing mini-course: https://MixMasterBundle.com My guest today is Gabe Dagrezio. Gabe started as the frontman of The New Story, an Italian touring band signed to EMI/Virgin in the early 2000s. His time in the studio sparked a deep passion for recording, leading him to master performance, engineering, and production. Gabe is a skilled guitarist, songwriter, and singer who has performed thousands of shows worldwide. His background gives him a performer's sensitivity in the studio, bridging the gap between artistry and technical precision. With a Bachelor of Music in Songwriting, Contemporary Guitar, and Music Technology, he brings a well-rounded approach to recording, mixing, and coaching artists to their best performances. We met a couple years ago and here's a quote from Gabe “NAMM, I walked up to you because I listen to your podcast, and I recognized the voice, then, I looked at your badge :)” THANKS TO OUR SPONSORS! http://UltimateMixingMasterclass.com https://usa.sae.edu/ https://www.izotope.com Use code ROCK10 to get 10% off! https://www.native-instruments.com Use code ROCK10 to get 10% off! https://www.adam-audio.com/ https://www.makebelievestudio.com/mbsi Get your MBSI plugin here! https://RecordingStudioRockstars.com/Academy  https://www.thetoyboxstudio.com/ Listen to the podcast theme song “Skadoosh!” https://solo.to/lijshawmusic Listen to this guest's discography on Soundcloud: Recent productions: https://on.soundcloud.com/BMSg25zFjH4crFA99 Original songs: https://on.soundcloud.com/YVPKzB29pob8UAy9A If you love the podcast, then please leave a review: https://RSRockstars.com/Review CLICK HERE FOR COMPLETE SHOW NOTES AT: https://RSRockstars.com/519

1.   ¡Campeones! Los Vaqueros completan su temporadade ensueño con su título número 17. Bayamón venció a los Leones de Ponce en elquinto partido de la final para regresar a la cima de la liga después de tresaños.2.   La verdad detrás de las pugnas entre DaddyYankee y su esposa3.   Le respondo a El Molusco4.   Island on Edge: Trump Board Shake-Up SparksFears in Puerto Rico / Isla al límite: La reorganización de la JCF de Trumpgenera temores en Puerto Rico5.  ASES confirmadesembolso millonario a aseguradoras del Plan Vital y recuerda el plazo de 15días para pagar a los proveedores6.  Desconfían de próximaconvocatoria: “La EPA lavará la cara de AES”7.  Cero “wheelies” en lascarreteras8.   Trump inicia el “golpe de estado” [moviliza injustificadamente a laGuardia Nacional en WashingtonEste es un programa independiente y sindicalizado. Esto significa que este programa se produce de manera independiente, pero se transmite de manera sindicalizada, o sea, por las emisoras y cadenas de radio que son más fuertes en sus respectivas regiones. También se transmite por sus plataformas digitales, aplicaciones para dispositivos móviles y redes sociales.  Estas emisoras de radio son:1.    Cadena WIAC - WYAC 930 AM Cabo Rojo- Mayagüez2.    Cadena WIAC – WISA 1390 AM Isabela3.    Cadena WIAC – WIAC 740 AM Área norte y zona metropolitana4.    WLRP 1460 AM Radio Raíces La voz del Pepino en San Sebastián5.    X61 – 610 AM en Patillas6.    X61 – 94.3 FM Patillas y todo el sureste7.    WPAB 550 AM - Ponce8.    ECO 93.1 FM – En todo Puerto Rico9.    WOQI 1020 AM – Radio Casa Pueblo desde Adjuntas 10. Mundo Latino PR.com, la emisora web de música tropical y comentario Una vez sale del aire, el programa queda grabado y está disponible en las plataformas de podcasts tales como Spotify, Soundcloud, Apple Podcasts, Google Podcasts y otras plataformas https://anchor.fm/sandrarodriguezcotto También nos pueden seguir en:REDES SOCIALES:  Facebook, X (Twitter), Instagram, Threads, LinkedIn, Tumblr, TikTok BLOG:  En Blanco y Negro con Sandra http://enblancoynegromedia.blogspot.com  SUSCRIPCIÓN: Substack, plataforma de suscripción de prensa independientehttps://substack.com/@sandrarodriguezcotto OTROS MEDIOS DIGITALES: ¡Ey! Boricua, Revista Seguros. Revista Crónicas y otrosEstas son algunas de las noticias que tenemos hoy En Blanco y Negro con Sandra. 9.  Seis periodistasasesinados en Gaza: ¿quiénes eran y cómo y por qué los mató Israel?

Why you should listenCyril Louis shares how Mavericx transformed from a typical Salesforce implementation partner into a trusted CX advisor, offering a proven blueprint for boutique firms looking to escape the commodity trap.Learn how building and leading local communities for 10+ years became a powerful lead generation and recruitment strategy that costs nothing but delivers exponentially.Discover practical AI implementation strategies across retail and financial services, including the step-by-step maturity model that prevents costly AI pilot failures.If you're tired of competing on price with every other Salesforce partner and watching the big SIs walk away with the strategic work while you get stuck doing configurations, this episode will change how you think about positioning. Boutique after boutique races to the bottom, begging for leads from AEs who now expect you to bring them business instead of partnering with you. That's exactly where Cyril Louis from Mavericx was heading until his clients started asking him a different question: "What's next after Salesforce?" Instead of just implementing CRM, Cyril repositioned his firm as the CX strategy partner who happens to know Salesforce inside out. We break down his 10-year community play that's generated more qualified leads than any marketing campaign, his three-stage AI framework that prevents those expensive pilot disasters, and the hard lesson about saying no to bad-fit clients earlier.About Cyril LouisCyril has 17 years of experience in digital and cultivates a dual skill by focusing on CRM topics & customer knowledge as well as on engagement & digital marketing aspects.He worked on numerous missions aimed at defining new strategies as ‘Customer Centric Company‘ and ‘Data Driven Company‘ via customer journeys for a better engagement. These new customer journeys involve many reflections on organization, methodologies, data urbanization and IT architecture. Cyril regularly shares thoughts and best practices on topics around the omni-channel customer experience, whether in publications or at diverse conferences.His expertise has been recognized by Salesforce with his awards as Salesforce MVP, Salesforce Lightning Champion and Salesforce User Group Leader.Resources and LinksMavericx.chCyril's LinkedIn profileChatGPTClaude.aiCursorOnyxPrevious episode: 627 - SMS Isn't Spam: It's Your 98% Open Rate Gold Mine with Chris BrissonCheck out more episodes of the Paul Higgins PodcastSubscribe to our YouTube channel: @PaulHigginsMentoringFree Training for AI & Tech Consultants Ready to Stop Trading Time for MoneyJoin our newsletter

In a conversation with CancerNetwork® at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference, Tiba Al Sagheer, PharmD, BCOP, BCACP; Rebecca Gonzalez, PharmD, BCOP, FASTCT; and Syeda Saba Kareem PharmD, BCOP, spoke about their presentations on managing adverse effects (AEs) across different hematologic malignancy populations. At the meeting, Al Sagheer, Gonzalez, and Kareem presented their ideas for treating patients with lymphoma, leukemia, and multiple myeloma, respectively. Al Sagheer is a Pharmacy Quality Improvement Coordinator and Transplant/Cellular Therapy and Hematology Clinical Pharmacy Specialist at Miami Cancer Institute of Baptist Health South Florida. Gonzalez is a clinical pharmacy specialist in Blood and Marrow Transplantation and Cellular Immunotherapy at Moffitt Cancer Center. Kareem is a clinical pharmacy supervisor in Malignant Hematology at Moffitt Cancer Center. Across different disease states, the presenters outlined the most common toxicities associated with CAR T-cell therapy, bispecific antibodies, and other novel immunotherapies. Additionally, they described strategies for reducing the severity of AEs such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome as well as other oral, dermatological, and nail toxicities. Other key considerations for preserving quality of life among those receiving cellular therapy included risk stratifying patients based on tumor burden and inflammatory markers at baseline to inform prophylactic measures. Each presenter shared key takeaways for treating patients who experience treatment-related AEs based on their individual presentations. Al Sagheer emphasized that it is not “one size fits all” when it comes to therapy, as providers must tailor their use of specific drugs, prophylactic measures, and anti-infective medication to each individual patient. Kareem noted that cellular therapy represents an evolving field, as toxicity mitigation strategies will continue to change over time as new data emerge. Finally, Gonzalez underscored the intimate nature of the cellular therapy field, which presents opportunities to collaborate with other institutions and receive guidance on managing complex cases.  References Al Sagheer T. Mastering the management of adverse effects from cellular therapies in lymphoma. Presented at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference; July 26, 2025; Orlando, FL. Gonzalez R. Navigating the challenges: managing adverse effects of cellular therapies in ALL. Presented at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference; July 26, 2025; Orlando, FL. Kareem SS. Management of adverse events of CAR-T and T-cell engagers in myeloma. Presented at the 2025 National Immune Cell Effector Therapy (ICE-T) Conference; July 26, 2025; Orlando, FL.

What happens when a top-performing rep becomes a people-first leader in one of the most demanding roles in tech? In this episode of Coach2Scale, Jeff Perry, CRO at Carta, shares his leadership journey from his early days at Oracle to building high-performing, diverse teams at Carta. He unpacks the misconceptions that still hold sales leaders back, like the idea that only hard-charging, deal-focused managers succeed, or that considerable company experience doesn't translate to startup growth. Jeff challenges these myths with candor, offering lessons for anyone navigating their evolution as a leader.The conversation tackles why being a “nice leader” isn't a liability, how to hire from non-obvious backgrounds, and why no one should ever lose a deal alone. Matt and Jeff also dig into the most challenging job in sales, the frontline manager, and why equipping them with the right mindset and tools is the only way to scale performance sustainably. Whether you're a rep, manager, or CRO, this episode will help you rethink how leadership, culture, and coaching intersect to drive lasting results.Key Takeaways1. Lean into who you are as a leaderStop trying to fit someone else's mold, own your style, values, and story to build authentic credibility.2. Prominent company leaders can thrive in startups.Success in enterprise sales doesn't disqualify you from excelling in high-growth, early-stage environments if you can translate your experience.3. Empathy and accountability are not mutually exclusiveBeing a “nice” leader doesn't mean being soft; it means building trust so you can challenge and develop your people effectively.4. Hiring for diversity improves team performance.Creating teams with varied backgrounds and experiences, not just résumés, leads to more resilience, learning, and results.5. Balanced team performance is more sustainable than star-centric modelsHitting 115% with everyone contributing beats 130% with a few carrying the load, especially when building culture and scale.7. Managers should never lose a deal alone.The best AEs use the entire team, from executives to product, to win; lone-wolf selling is inefficient and risky.8. Coaching should focus beyond the deal.Too many 1:1s revolve around the pipeline; great leaders use coaching to build reps' long-term skills and confidence.9. Sales leadership is about consistency through volatilityIn unpredictable markets, reps need leaders who are steady, transparent, and focused on what can be controlled.10. High growth creates opportunity, but only for those who embrace itCarta's rapid evolution has opened new career paths, but leaders must stay close to the people and remain hands-on to unlock them.11. Frontline managers need structure and support to succeedThe FLM role is the most overloaded in the org; without tools, coaching frameworks, and clarity, they default to dealing with triage and burnout.

D.O. explains the true role of Account Executives ("the plug") in the mortgage world and breaks down how AEs provide unparalleled value to brokers—not just with competitive rates, but through deal structuring expertise, business coaching, and driving growth with event marketing. Whether you're a mortgage veteran or curious about the AE path, this episode gives actionable strategies for success and uncovers surprising parallels between AE-broker and LO-realtor partnerships.

Wed July 30, 2025 Audience: Any family with a DEE who has a kid who has seizures, yes SYNGAP1 is a DEE and you are always my first audience.   See #S10e133 if you are curious about DEE vs other names. https://curesyngap1.org/podcasts/syngap10/what-is-this-syngap1-illness-disease-syndrome-ndd-dee-mrd5-nsid-actually-called-s10e133/   Action: If your kid has motor seizures, fill out the screener and join this amazing study. Link here: https://www.resiliencestudies.com/emerald   A motor seizure is a seizure where you can see something moving – including head drops, drops, convulsive, etc. – only excluded seizures are absence, myoclonia and infantile spasms.  You don't need to figure this out, just fill in the screener, let the doctors figure it out.   Questions: Come to live webinar tomorrow, it will not be recorded, so you have to come register here: https://curesyngap1.org/resources/webinars/webinar-111-introduction-to-praxiss-emerald-study-for-syngap1-patients/   TRIAL. Any DEE patient with 4 motor seizures a month, minimum. Age 2-65.  Adults are you listening? 24 weeks (6 months) weeks, placebo controlled but everyone will get drug at some point in the trial. 28 weeks (7 months) week OLE, with a chance for expanded access, so if it works, you can stay on. Fully decentralized, you don't have to go to a site if you don't want to. One US site open so far in Bethesda, there will be others.  Int'l sites in 2026.  US ENROLLING NOW. DRUG. Lots of science and big words in the links below, but here is what you need to know as a parent. It's a liquid, can go oral or in a g-tube. There is no ramp up, you put it in and it works.  In terms of speed, think Lorazepam not Lamotrigine. It's potent and specific, which means small volume.  Roughly 1ml for 10 kg.  This will be a rounding error in the face of a normal SynGAPian med regime. Even though this is a sodium channel drug, it should benefit all DEEs b/c, good to clarify tomorrow, all seizures end with a hyperactive sodium channel firing and that is what Relutragine focuses on.   PRAXIS. Serious people, lots of work on Epilepsy.  Connected to SYNGAP1 and DEEs, just need to move faster on SYNGAP1 ASO! CSO is Steve Petrou, works with SRF AUS and knows they are waiting. KD and AN started a company for SCN2A and it was absorbed by Praxis, they are still there and are relentless. Work on both small molecules and ASO, this is a way for them to see our team in action.   Cool links: AES 2024 Story. https://eppro01.ativ.me/web/page.php?page=session&project=AES24&id=2894147 Embold read out: https://www.neurologylive.com/view/relutrigine-shows-promise-phase-2-embold-study-scn2a-dee-scn8a-dee FDA Breakthrough. https://www.globenewswire.com/news-release/2025/07/17/3117145/0/en/Praxis-Precision-Medicines-Receives-FDA-Breakthrough-Therapy-Designation-for-Relutrigine-for-the-Treatment-of-Seizures-Associated-with-SCN2A-and-SCN8A-Developmental-and-Epileptic-E.html More links. https://delta.larvol.com/Products/?ProductId=05ccb036-a308-4249-abf6-e03b120839da   Why am I doing this? We need better meds and the way to meds is through trials. We need to jump at every trial, every time. 3. This one is decentralized, so minimum burden. If you get in now, this will be over before it's ASO trial time, so you could do both. Our Syngapians with motor seizures tend to be our most severe, we have to make sure we find out if this drug can help.  All our kids may progress to this point.   See you at the webinar, fill out the screener now: https://www.resiliencestudies.com/emerald

Drum Corps History, Shower Anthems & Duct‑Tape Marching Tux TriumphYour All‑Access Pass to the Marching Arts. A Podcast for Marching Arts Enthusiasts—On the Field, In the Stands & Behind the Scenes.This week hosts Nicole Younger, Jackie Brown, and Trish O'Shea welcome Tai Nelson from Ty Talks DCI (@taitalksdci) to dive into the deeper story behind drum corps—from academic roots to Instagram education and yes, shower anthems.Surprise guest Nicholas Moore (@BrasstapeBandKid on IG, @BrassTape on TikTok) joins us live from Disney to celebrate his $15,000 Duck Brand “Stuck at Prom” win, featuring his viral duct‑tape tux!

What happens when a solar technician calls themselves a “Level 2,” but no one knows what that actually means?For years, solar O&M has lacked the structure and standardization seen in other trades. The result? Confusing job titles, wage inflation, inconsistent training, and safety risks. But that's all about to change.In this Tactical Tuesday episode, Nico Johnson is joined by Amanda Bybee, CEO of Amicus O&M Cooperative, and Karo Fernandez, Technical Training manager at AES Clean Energy. Together, they have helped create and rollout ANSI/SEIA 301, the first ANSI-accredited standard defining technician levels in the solar industry! They share how a diverse coalition of stakeholders—from co-ops to giants like AES—came together to define skill levels, competencies, and a real career ladder for solar techs.Amanda breaks down the origin of the standard, why it's necessary, and how it was shaped through broad consensus (60+ companies!). Karo brings it to life, showing how AES is rolling out hands-on, real-world training that prioritizes safety and clarity.If your business hires solar technicians—or wants to keep them—this episode is a must-listen.Expect to Learn:

Yes, $8 trillion. Nigam Arora believes Nvidia (NVDA) can double its value with the A.I. landscape set to evolve over the coming years. He sees robotics leading the next leg of Nvidia's growth, as Nigam sees humanoid robotics becoming upwards of a $3 trillion industry. He also gives investors a roadmap into how they can manage positions. He later talks about buyout candidates which include AES Corp. (AES) and Verint (VRNT).======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Most orgs spend weeks training reps on the product… but months later, you're still stuck with an empty pipeline. What if the key to ramping AEs faster was skipping product training (at first)? Kyle Asay (VP Global Growth Sales @ LaunchDarkly) shares how his team cut time to first deal by 49% by rethinking onboarding. Instead of starting with feature dumps, they focused on: ✅ Account prioritization ✅ Customer problems & personas ✅ Story-based selling If you lead a team or are ramping yourself, don't miss this one. RESOURCES DISCUSSED: ⁠⁠Join our weekly newsletter⁠⁠ ⁠⁠Things you can steal⁠⁠ ⁠⁠Save $50 on any 30MPC course⁠⁠ with code “PODCAST” ⁠⁠Free Sales Templates, Scripts and Guides

In this episode, I explore the difference between the military mindset and the more stealth approach of minimization in cybersecurity. I share the results from the Ghost in the Source Capture the Flag (CTF) challenge, revealing how the winners cracked the AES encryption using dictionary attacks, keyword harvesting and the cipher tool hidden in robots.txt. I discuss why the “assume breach” mentality just leaves the doors wide open, using examples from Kevin Mitnick's 1981 Pacific Bell infiltration to modern ransomware groups like Scattered Spider who breached MGM and Marks & Spencer through social engineering.I also cover practical tactics for using public Wi-Fi, data curation techniques, the invisible surveillance net including Stingray devices, and provide a deep dive into GrapheneOS covering user profiles, app sandboxing, network controls, sensor permissions, and the proper use of sandboxed Google Play services.In this week's episode:Ghost in the Source Capture the Flag challenge resultsThe military mindset problem in cybersecurityStrategic use of public Wi-Fi for account creation and privacy techniquesData curation tactics, and “Minimizing What Can Be Known”Invisible surveillance net and Stingray devicesGrapheneOS discussion on user profiles, app sandboxing, network controls, sensors permissions, sandboxed Google Play services, and security architectureMatrix Community RoomsMatrix Community Space - https://matrix.to/#/#psysecure:matrix.orgIndividual Room Links:https://matrix.to/#/#lockdown-general:matrix.orghttps://matrix.to/#/#lockdown-podcast:matrix.orghttps://matrix.to/#/#lockdown-intro:matrix.orgShow Links:Noam Chomsky on Internet Privacyhttps://www.youtube.com/watch?v=QIWsTMcBrjQNoam Chomsky on Advertising - https://www.youtube.com/watch?v=PfIwUlY44CMTryHackMe Platform - https://tryhackme.comHack the Box - https://hackthebox.comWired Article on DNC Stingray Surveillance - https://www.wired.com/story/2024-dnc-cell-site-simulator-phone-surveillance/IntelTechniques Data Removal Guide - https://inteltechniques.com/workbook.htmlOptery Data Broker Removal - https://optery.comGraphene OS - https://grapheneos.org“We're dragons. We're not supposed to live by other people's rules.”- Hajime Ryudo ★ Support this podcast on Patreon ★

In this unfiltered episode of The E1B2 Collective, I talk about something too many revenue leaders miss: career mapping for AEs who don't fit the traditional mold. Not every seller is a closer—but that doesn't mean they aren't valuable. Some build trust. Some extend customer lifetime value. Some become the bridge to new markets, new partners, and long-term growth.I've seen too many talented AEs mismanaged, undervalued, and pushed out because they didn't meet a narrow definition of success. This episode is a call to rethink how we design sales orgs—with learning academies, better mentorship, and room for real human contribution beyond the number.

Are you using Polars for your data science work? Maybe you've been sticking with the tried-and-true Pandas? There are many benefits to Polars directly of course. But you might not be aware of all the excellent tools and libraries that make Polars even better. Examples include Patito which combines Pydantic and Polars for data validation and polars_encryption which adds AES encryption to selected columns. We have Christopher Trudeau back on Talk Python To Me to tell us about his list of excellent libraries to power up your Polars game and we also talk a bit about his new Polars course. Episode sponsors Agntcy Sentry Error Monitoring, Code TALKPYTHON Talk Python Courses Links from the show New Theme Song (Full-Length Download and backstory): talkpython.fm/blog Polars for Power Users Course: training.talkpython.fm Awesome Polars: github.com Polars Visualization with Plotly: docs.pola.rs Dataframely: github.com Patito: github.com polars_iptools: github.com polars-fuzzy-match: github.com Nucleo Fuzzy Matcher: github.com polars-strsim: github.com polars_encryption: github.com polars-xdt: github.com polars_ols: github.com Least Mean Squares Filter in Signal Processing: www.geeksforgeeks.org polars-pairing: github.com Pairing Function: en.wikipedia.org polars_list_utils: github.com Harley Schema Helpers: tomburdge.github.io Marimo Reactive Notebooks Episode: talkpython.fm Marimo: marimo.io Ahoy Narwhals Podcast Episode Links: talkpython.fm Watch this episode on YouTube: youtube.com Episode #510 deep-dive: talkpython.fm/510 Episode transcripts: talkpython.fm --- Stay in touch with us --- Subscribe to Talk Python on YouTube: youtube.com Talk Python on Bluesky: @talkpython.fm at bsky.app Talk Python on Mastodon: talkpython Michael on Bluesky: @mkennedy.codes at bsky.app Michael on Mastodon: mkennedy

Rep. Pryor (Dem. District 94) joined the show to talk about AES's plan on increasing their rates and how it will negatively affect Hoosiers. See omnystudio.com/listener for privacy information.

Hour 3 Segment 1 Kendall & Casey starts the final hour of the show talking about the big, beautiful bill. They also talk about a North Vernon man organizing a meeting to address rising property assessments. They later talk about the massive traffic jam yesterday after the Pacers gave out 5000 swag bags. Hour 3 Segment 2 Kendall & Casey talk about the Indiana politicians betting with Oklahoma politicians for the Pacers and Thunder for the NBA Finals. Hour 3 Segment 3 Kendall & Casey talk about Rob going to a town hall meeting yesterday in Brownsburg. Hour 3 Segment 4 Kendall & Casey wrap up another edition of the show talking more about the AES price increase. They also talk about not making the 2025 Indiana Broadcast Pioneers Hall of Fame. See omnystudio.com/listener for privacy information.

Kendall & Casey wrap up the second hour joined by Jason Hammer to talk more about their upcoming show tomorrow at Horeshoe Indy Casino in Shelbyville. They also talk about AES wanting price increases. See omnystudio.com/listener for privacy information.

Hour 2 Segment 1 Kendall & Casey start the second hour of the show talking about Elon Musk not being in favor of President Donald Trump’s big, beautiful bill. Hour 2 Segment 2 Kendall & Casey talk about Indiana Governor Mike Braun saying he’s open to debate for the future of the death penalty. Hour 2 Segment 3 Kendall & Casey talk about AES wanting prices to increase. They also talk about a new sports bar in Indianapolis that only shows women’s sports. Hour 2 Segment 4 Kendall & Casey wrap up the second hour joined by Jason Hammer to talk more about their upcoming show tomorrow at Horeshoe Indy Casino in Shelbyville. They also talk about AES wanting price increases. See omnystudio.com/listener for privacy information.